News | November 01, 2023
Ajanta Pharma posts Q2 FY24 consolidated PAT at Rs. 195.30 Cr
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
The inspection of the facility conducted from August 7 to August 11, 2023
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
The company has reported total income of Rs. 486.16 crores during the period ended September 30, 2023
Aarti Drugs has reported total income of Rs. 642.22 crores during the period ended September 30, 2023
Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated
